Inverse agonist properties of atypical antipsychotic drugs
- 1 June 2004
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 67 (11) , 2039-2045
- https://doi.org/10.1016/j.bcp.2004.02.017
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Atypical antipsychotics: are some more atypical than others?Psychopharmacology, 2000
- Contribution of Serine Residues to Constitutive and Agonist-Induced Signaling via the D2SDopamine Receptor: Evidence for Multiple, Agonist-Specific Active ConformationsMolecular Pharmacology, 1998
- The cerebral cortex: a case for a common site of action of antipsychoticsTrends in Pharmacological Sciences, 1998
- Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptorsBritish Journal of Pharmacology, 1997
- What Makes an Antipsychotic ‘Atypical’?CNS Drugs, 1997
- What Makes an Antipsychotic ‘Atypical’?CNS Drugs, 1997
- Antipsychotics with inverse agonist activity at the dopamine D3 receptorJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- Dopamine receptor pharmacologyTrends in Pharmacological Sciences, 1994
- Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- NeurolepticsPublished by Springer Nature ,1985